A Study to Evaluate Alloantibody Titer in Highly Sensitized Kidney Transplant Candidates

Overview

About this study

The purpose of this study is to evaluate the utility of using anti-HLA antibody titer to measure the effectiveness of antibody lowering therapy (i.e., desensitization) in highly-sensitized kidney transplant candidates.

 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Please contact the study team to discuss whether or not you are eligible to participate in a study.

Inclusion Criteria:

  • Kidney and/or pancreas transplant candidates with calculated panel reactive antibodies > 99% (this is a measure of sensitization, not age).

Exclusion Criteria: 

  • Receipt of a blood transfusion, transplant, or transplant nephrectomy within the 6-9 month follow-up between sample collection.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Mark Stegall, M.D.

Contact us for the latest status

Contact information:

Katelyn Register

127or7838503

Register.Katelyn@mayo.edu

Rochester, Minn.

Mayo Clinic principal investigator

Mark Stegall, M.D.

Contact us for the latest status

Contact information:

Mark Stegall M.D.

Stegall.Mark@mayo.edu

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Mark Stegall, M.D.

Contact us for the latest status

Contact information:

Raymond Heilman M.D.

(480)342-0161

heilman.raymond@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available